Your browser doesn't support javascript.
loading
Exploring rat corpus cavernosum alterations induced by finasteride treatment and withdrawal.
Diviccaro, Silvia; Herian, Monika; Cioffi, Lucia; Audano, Matteo; Mitro, Nico; Caruso, Donatella; Giatti, Silvia; Melcangi, Roberto Cosimo.
Affiliation
  • Diviccaro S; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
  • Herian M; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
  • Cioffi L; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
  • Audano M; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
  • Mitro N; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
  • Caruso D; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
  • Giatti S; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
  • Melcangi RC; Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milano, Italy.
Andrology ; 12(3): 674-681, 2024 Mar.
Article in En | MEDLINE | ID: mdl-37621185
Despite its efficacy for treating androgenetic alopecia, finasteride, an inhibitor of 5α-reductase (i.e., the enzyme converting testosterone, T, into dihydrotestosterone, DHT), is associated with several side effects including sexual dysfunction (e.g., erectile dysfunction). These side effects may persist after drug suspension, inducing the so-called post-finasteride syndrome (PFS). The effects of subchronic treatment with finasteride (i.e., 20 days) and its withdrawal (i.e., 1 month) in rat corpus cavernosum have been explored here. Data obtained show that the treatment was able to decrease the levels of the enzyme 5α-reductase type II in the rat corpus cavernosum with increased T and decreased DHT levels. This local change in T metabolism was linked to mechanisms associated with erectile dysfunction. Indeed, by targeted metabolomics, we reported a decrease in the nitric oxide synthase (NOS) activity, measured by the citrulline/arginine ratio and confirmed by the decrease in NO2 levels, and a decrease in ornithine transcarbamylase (OTC) activity, measured by citrulline/ornithine ratio. Interestingly, the T levels are negatively correlated with NOS activity, while those of DHT are positively correlated with OTC activity. Finasteride treatment also induced alterations in the levels of other molecules involved in the control of penile erection, such as norepinephrine and its metabolite, epinephrine. Indeed, plasma levels of norepinephrine and epinephrine were significantly increased and decreased, respectively, suggesting an impairment of these mediators. Interestingly, these modifications were restored by suspension of the drug. Altogether, the results reported here indicate that finasteride treatment, but not its withdrawal, affects T metabolism in the rat corpus cavernosum, and this alteration was linked to mechanisms associated with erectile dysfunction. Data here reported could also suggest that the PFS sexual side effects are more related to dysfunction in a sexual central control rather than peripheral compromised condition.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Finasteride / Erectile Dysfunction Limits: Animals / Humans / Male Language: En Journal: Andrology Year: 2024 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Finasteride / Erectile Dysfunction Limits: Animals / Humans / Male Language: En Journal: Andrology Year: 2024 Document type: Article Affiliation country: Italy Country of publication: United kingdom